Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
19
12
2019
revised:
19
02
2020
accepted:
16
03
2020
pubmed:
18
7
2020
medline:
7
1
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
The Greater Mekong subregion is a recurrent source of antimalarial drug resistance in Plasmodium falciparum malaria. This study aimed to characterise the extent and spread of resistance across this entire region between 2007 and 2018. P falciparum isolates from Myanmar, Thailand, Laos, and Cambodia were obtained from clinical trials and epidemiological studies done between Jan 1, 2007, and Dec 31, 2018, and were genotyped for molecular markers (pfkelch, pfcrt, pfplasmepsin2, and pfmdr1) of antimalarial drug resistance. Genetic relatedness was assessed using microsatellite and single nucleotide polymorphism typing of flanking sequences around target genes. 10 632 isolates were genotyped. A single long pfkelch Cys580Tyr haplotype (from -50 kb to +31·5 kb) conferring artemisinin resistance (PfPailin) now dominates across the eastern Greater Mekong subregion. Piperaquine resistance associated with pfplasmepsin2 gene amplification and mutations in pfcrt downstream of the Lys76Thr chloroquine resistance locus has also developed. On the Thailand-Myanmar border a different pfkelch Cys580Tyr lineage rose to high frequencies before it was eliminated. Elsewhere in Myanmar the Cys580Tyr allele remains widespread at low allele frequencies. Meanwhile a single artemisinin-resistant pfkelch Phe446Ile haplotype has spread across Myanmar. Despite intense use of dihydroartemisinin-piperaquine in Kayin state, eastern Myanmar, both in treatment and mass drug administrations, no selection of piperaquine resistance markers was observed. pfmdr1 amplification, a marker of resistance to mefloquine, remains at low prevalence across the entire region. Artemisinin resistance in P falciparum is now prevalent across the Greater Mekong subregion. In the eastern Greater Mekong subregion a multidrug resistant P falciparum lineage (PfPailin) dominates. In Myanmar a long pfkelch Phe446Ile haplotype has spread widely but, by contrast with the eastern Greater Mekong subregion, there is no indication of artemisinin combination therapy (ACT) partner drug resistance from genotyping known markers, and no evidence of spread of ACT resistant P falciparum from the east to the west. There is still a window of opportunity to prevent global spread of ACT resistance. Thailand Science Research and Innovation, Initiative 5%, Expertise France, Wellcome Trust.
Sections du résumé
BACKGROUND
The Greater Mekong subregion is a recurrent source of antimalarial drug resistance in Plasmodium falciparum malaria. This study aimed to characterise the extent and spread of resistance across this entire region between 2007 and 2018.
METHODS
P falciparum isolates from Myanmar, Thailand, Laos, and Cambodia were obtained from clinical trials and epidemiological studies done between Jan 1, 2007, and Dec 31, 2018, and were genotyped for molecular markers (pfkelch, pfcrt, pfplasmepsin2, and pfmdr1) of antimalarial drug resistance. Genetic relatedness was assessed using microsatellite and single nucleotide polymorphism typing of flanking sequences around target genes.
FINDINGS
10 632 isolates were genotyped. A single long pfkelch Cys580Tyr haplotype (from -50 kb to +31·5 kb) conferring artemisinin resistance (PfPailin) now dominates across the eastern Greater Mekong subregion. Piperaquine resistance associated with pfplasmepsin2 gene amplification and mutations in pfcrt downstream of the Lys76Thr chloroquine resistance locus has also developed. On the Thailand-Myanmar border a different pfkelch Cys580Tyr lineage rose to high frequencies before it was eliminated. Elsewhere in Myanmar the Cys580Tyr allele remains widespread at low allele frequencies. Meanwhile a single artemisinin-resistant pfkelch Phe446Ile haplotype has spread across Myanmar. Despite intense use of dihydroartemisinin-piperaquine in Kayin state, eastern Myanmar, both in treatment and mass drug administrations, no selection of piperaquine resistance markers was observed. pfmdr1 amplification, a marker of resistance to mefloquine, remains at low prevalence across the entire region.
INTERPRETATION
Artemisinin resistance in P falciparum is now prevalent across the Greater Mekong subregion. In the eastern Greater Mekong subregion a multidrug resistant P falciparum lineage (PfPailin) dominates. In Myanmar a long pfkelch Phe446Ile haplotype has spread widely but, by contrast with the eastern Greater Mekong subregion, there is no indication of artemisinin combination therapy (ACT) partner drug resistance from genotyping known markers, and no evidence of spread of ACT resistant P falciparum from the east to the west. There is still a window of opportunity to prevent global spread of ACT resistance.
FUNDING
Thailand Science Research and Innovation, Initiative 5%, Expertise France, Wellcome Trust.
Identifiants
pubmed: 32679084
pii: S1473-3099(20)30228-0
doi: 10.1016/S1473-3099(20)30228-0
pmc: PMC7689289
pii:
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Genetic Markers
0
artemisinin
9RMU91N5K2
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1470-1480Subventions
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106698/B/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101148/Z/13/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
BMC Med. 2018 Oct 22;16(1):183
pubmed: 30343666
Malar J. 2015 Sep 30;14:381
pubmed: 26424000
Malar J. 2018 Jul 11;17(1):258
pubmed: 29996844
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Clin Infect Dis. 2006 Jun 1;42(11):1570-7
pubmed: 16652314
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Nature. 2019 Dec;576(7786):315-320
pubmed: 31776516
Nat Commun. 2018 May 2;9(1):1769
pubmed: 29720620
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
Malar J. 2015 Apr 18;14:168
pubmed: 25927592
Lancet Infect Dis. 2015 Apr;15(4):415-21
pubmed: 25704894
Malar J. 2016 Mar 31;15:185
pubmed: 27036739
J Infect Dis. 2015 Mar 1;211(5):670-9
pubmed: 25180241
Lancet Infect Dis. 2017 Oct;17(10):1022-1023
pubmed: 28948924
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Nat Genet. 2013 Jun;45(6):648-55
pubmed: 23624527
Nat Commun. 2019 Dec 6;10(1):5595
pubmed: 31811128
Mol Biol Evol. 2017 Jan;34(1):131-144
pubmed: 28025270
Lancet Infect Dis. 2017 Jan;17(1):e15-e20
pubmed: 27839929
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
J Infect Dis. 2015 Nov 15;212(10):1629-35
pubmed: 25910630
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
PLoS One. 2009;4(2):e4551
pubmed: 19234601
J Infect Dis. 2019 Apr 16;219(9):1499-1509
pubmed: 30500927
Malar J. 2017 Jan 13;16(1):27
pubmed: 28086775
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425